Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 21 12:40PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-0.91 Insider Own53.54% Shs Outstand253.96M Perf Week-20.49%
Market Cap525.00M Forward P/E- EPS next Y-0.91 Insider Trans0.00% Shs Float118.44M Perf Month-21.10%
Income-228.34M PEG- EPS next Q-0.20 Inst Own28.30% Short Float17.05% Perf Quarter0.95%
Sales0.07M P/S7499.97 EPS this Y6.76% Inst Trans4.23% Short Ratio25.78 Perf Half Y-0.03%
Book/sh2.37 P/B0.87 EPS next Y-4.50% ROA-29.00% Short Interest20.20M Perf Year-35.45%
Cash/sh2.06 P/C1.00 EPS next 5Y-7.90% ROE-32.93% 52W Range1.32 - 3.41 Perf YTD6.15%
Dividend Est.- P/FCF- EPS past 5Y-15.28% ROI-34.69% 52W High-39.61% Beta-0.47
Dividend TTM- Quick Ratio16.51 Sales past 5Y428.28% Gross Margin-28905.88% 52W Low56.01% ATR (14)0.18
Dividend Ex-Date- Current Ratio16.51 EPS Y/Y TTM-23.64% Oper. Margin-356494.12% RSI (14)36.19 Volatility7.88% 7.10%
Employees224 Debt/Eq0.10 Sales Y/Y TTM-99.92% Profit Margin-335794.12% Recom1.67 Target Price7.50
Option/ShortYes / Yes LT Debt/Eq0.09 EPS Q/Q11.07% Payout- Rel Volume2.55 Prev Close2.08
Sales Surprise200.00% EPS Surprise-8.77% Sales Q/Q-95.38% EarningsMay 06 BMO Avg Volume783.48K Price2.06
SMA20-18.33% SMA50-17.23% SMA200-0.98% Trades Volume1,025,797 Change-1.00%
Date Action Analyst Rating Change Price Target Change
Aug-28-23Downgrade JP Morgan Overweight → Neutral $15 → $5
Nov-14-22Downgrade Morgan Stanley Overweight → Equal-Weight $15 → $7
Nov-11-22Downgrade Goldman Buy → Neutral $13 → $7
Oct-17-22Initiated H.C. Wainwright Buy $12
Jul-12-21Initiated Morgan Stanley Overweight $25
Jul-12-21Initiated JP Morgan Overweight $22
Jul-12-21Initiated Goldman Buy $30
Jul-12-21Initiated BofA Securities Buy $25
Jun-03-24 04:05PM
May-07-24 04:05PM
May-06-24 10:53PM
08:00AM Loading…
Mar-19-24 10:00AM
Mar-07-24 12:00PM
Mar-05-24 04:30PM
Feb-28-24 04:44PM
Feb-26-24 04:05PM
Jan-03-24 04:05PM
Nov-09-23 04:05PM
Nov-07-23 04:33PM
04:05PM Loading…
Oct-31-23 09:00AM
Sep-27-23 09:00AM
Sep-11-23 08:00AM
Aug-31-23 04:05PM
Aug-08-23 07:10PM
Jul-12-23 08:47AM
Jul-05-23 04:05PM
Jun-16-23 10:47AM
Jun-07-23 04:05PM
Jun-01-23 07:55AM
May-04-23 07:25PM
04:05PM Loading…
May-02-23 04:05PM
Apr-17-23 07:11AM
Mar-27-23 04:52AM
Mar-26-23 10:14AM
Feb-28-23 08:15PM
Feb-02-23 06:43AM
Jan-03-23 04:05PM
Dec-23-22 06:36AM
Dec-16-22 10:48AM
Dec-15-22 07:00AM
Dec-09-22 09:35AM
Dec-01-22 04:05PM
Nov-12-22 07:39AM
Nov-10-22 04:05PM
Nov-08-22 07:15PM
Nov-07-22 08:05AM
Nov-04-22 10:00AM
Nov-02-22 04:05PM
Oct-25-22 07:59AM
Oct-17-22 12:54PM
Oct-06-22 04:05PM
Oct-05-22 08:05AM
Sep-28-22 04:05PM
Sep-15-22 09:40AM
Sep-12-22 09:55AM
Aug-30-22 04:05PM
Aug-26-22 09:55AM
Aug-10-22 09:55AM
Aug-08-22 06:30AM
Aug-04-22 06:25PM
Jul-17-22 09:49AM
Jun-30-22 01:08PM
Jun-17-22 07:38AM
Jun-07-22 04:05PM
May-25-22 03:00PM
May-10-22 04:05PM
May-09-22 11:29AM
May-05-22 09:31AM
May-04-22 04:05PM
May-03-22 09:55AM
May-02-22 04:30PM
Mar-29-22 04:05PM
Mar-20-22 08:02AM
Mar-16-22 06:26AM
Mar-08-22 04:45PM
Feb-17-22 04:38PM
Jan-31-22 04:05PM
Jan-24-22 12:39PM
Jan-19-22 11:11AM
Jan-15-22 08:31AM
Jan-04-22 04:05PM
Dec-16-21 04:05PM
Dec-15-21 04:05PM
Dec-02-21 04:05PM
Nov-16-21 08:49AM
Nov-12-21 08:00AM
Sep-30-21 06:01PM
Sep-17-21 10:16AM
Sep-08-21 04:05PM
Aug-12-21 04:05PM
Jul-18-21 11:39AM
Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Klausner RichardDirectorAug 15 '23Sale2.2858,020132,286930,880Aug 17 04:23 PM